Pixium Vision Is Setting its Sights on Finding a Buyer

2023-10-23
并购
Pixium Vision is looking for a buyer a little more than two years after ending a deal to acquire Second Sight Medical Products.
Last week, the Paris, France-based company and maker of bionic eye implants announced the launch of a process to find buyers. The company said it was undertaking this measure because it could not find financial investors within the restricted timeframe and in line with its needs.
The company said the deadline for submission of offers has been set by the court-appointed administrators to November 20, 2023 at 12:00 p.m.
Earlier this year, Pixium won breakthrough device designation for the Prima System, an implant to help treat dry age-related macular degeneration.
The designation came at a time when Pixium was well-removed from a merger attempt with Second Sight Medical Products. Pixium terminated plans to acquire the Second Sight company because the Sylmar, CA-based company filed for a private placement of $27.9 million. Pixium noted that placement violated the memorandum of understanding between the two.
Second Sight would go on to merge with Nano Precision Medical to be rebranded as Vivani Medical.
About a year after the merger plans were put on halt, a Paris Commercial Court ordered the merged company to pay Pixium $1.68 million for violating the MoU.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
药物
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。